Strofantin-Darnitsa (g-strophanthin) solution for injection 0.025% 1ml. ampoules №10

Description

Strofantin-Darnitsa (g-strophanthin) solution for injection 0.025% 1ml. ampoules №10

Composition

active substance: g-strophanthin;

1 ml of solution contains strophanthin G 0.25 mg;

Excipients: disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, disodium edetate, water for injections.

Dosage form

Solution for injection.

Basic physical and chemical properties: transparent colorless liquid.

Pharmacotherapeutic group

Cardiotonic drugs. Cardiac glycosides. G-strophanthin.
ATX code C01A C01.

Pharmacological properties

Strofantin-Darnitsa solution is a cardiac glycoside isolated from strophanthus gratus. It is one of the main “polar” cardiac glycosides. The drug has a cardiotonic effect, increases the strength and speed of myocardial contractions (positive inotropic effect), reduces heart rate (negative chronotropic effect), reduces atrioventricular conduction (negative dromotropic effect). In case of heart failure, it increases the stroke and minute volume of the heart, improves ventricular emptying, which leads to improved blood circulation.

Indication

Acute heart failure, chronic heart failure stage IIb-III (stage III-IV according to the classification of the New York Cardiac Association (NYHA)), supraventricular tachycardia, atrial fibrillation.

Contraindication

Hypersensitivity to the components of the drug. G. carotid sinus syndrome, thoracic aortic aneurysm, Wolff-Parkinson-White syndrome.

Use during pregnancy or breastfeeding

The drug is contraindicated during pregnancy or breastfeeding.

Method of application and dosage

The drug Strofantin-Darnitsa solutionshould be used intravenously in adults at a dose of 1-2 ml (dissolved in 10-20 ml of 0.9% sodium chloride solution). Inject slowly over 5-6 minutes. Assign the introduction of 1 or 2 times a day. If possible, it is better to administer the drug intravenously. To do this, dissolve 1 ml of the drug in 100 ml of 5% glucose solution or 0.9% sodium chloride solution. Drip injection reduces the likelihood of toxic effects. ECG monitoring should be performed 1 hour after intravenous administration. In case of frequent, group or polytopic ventricular arrhythmias, the drug should be discontinued and the next dose reduced by 2 times. Patients with renal insufficiency and elderly patients are recommended to administer the drug in reduced doses, starting with 0.125 mg, and then not exceeding 0.25 mg per day (except for emergencies).

If necessary, the single dose can be increased, for which an interval of 0.5−2 hours to enter an additional 0.1−0.15 mg (0.2−0.3 ml), with the maximum single dose should not exceed 0.25 mg , and daily – 1 mg (4 ml).

Children

There is no experience of using the drug in children, so it is not prescribed to children.

Overdose

Symptoms:

• from the cardiovascular system: atrioventricular block and cardiac arrhythmias, including bradycardia, ventricular paroxysmal tachycardia, ventricular arrhythmia, bigemia, polytopic ventricular tachycardia, SA-blockade, ventricular fibrillation and possible ventricular fibrillation, possible ventricular development;
• from the gastrointestinal tract: anorexia, nausea, vomiting, diarrhea, necrosis of the intestinal wall;
• from the nervous system: headache, dizziness, paresthesia, neuritis, radiculitis;

Treatment: discontinuation of the drug, the appointment of potassium and magnesium, parenteral unithiol. Further treatment is symptomatic, in ectopic arrhythmias prescribe antiarrhythmic drugs (lidocaine, diphenine, amiodarone).

Side effects:

• on the part of the visual organs: visual impairment;
• from the gastrointestinal tract: loss of appetite, nausea, vomiting, diarrhea, in severe cases – mesenteric infarction;
• from the endocrine system: gynecomastia in men (in isolated cases);
• from the nervous system: headache, dizziness, confusion, fatigue, drowsiness, sleep disturbances, mental disorders (depression, hallucinations, delirium psychosis);
• from the cardiovascular system: cardiac arrhythmia (bradyarrhythmia, ventricular tachycardia) and conduction (atrioventricular block);
• from the blood and lymphatic system: thrombocytopenic purpura, petechiae, nosebleeds;
• from the immune system: anaphylactic reactions, urticaria, allergic reactions;
• general disorders and administration site conditions: changes at the injection site.